ArticleClinical and translational medicine2021
Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma.
Article in Clinical and translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 29 citations in OpenAlex.
- A transcriptomic-based model associated with PARP inhibitor sensitivity and immunogenic signatures in ovarian cancer.Discover oncology · 2026Article
- Functional tumor-reactive CD8 + T cells in pancreatic cancer.Journal of experimental & clinical cancer research : CR · 2025Article
- Primary mucinous cystadenocarcinoma of the spleen: a case report and literature review.Frontiers in medicine · 2025Article
- Multi-omics decipher the immune microenvironment and unveil therapeutic strategies for postoperative ovarian cancer patients.Translational cancer research · 2024Article
- Machine learning for the identification of neoantigen-reactive CD8 + T cells in gastrointestinal cancer using single-cell sequencing.British journal of cancer · 2024Article
- Primary Serous Cystadenocarcinoma of the Spleen.Cureus · 2024Article
- Homologous recombination deficiency serves as a prognostic biomarker in clear cell renal cell carcinoma.Experimental and therapeutic medicine · 2023Article
- Targeting CXCL9/10/11-CXCR3 axis: an important component of tumor-promoting and antitumor immunity.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Review
- Genomic and molecular landscape of homologous recombination deficiency across multiple cancer types.Scientific reports · 2023Article
- The mechanism and clinical application of DNA damage repair inhibitors combined with immune checkpoint inhibitors in the treatment of urologic cancer.Frontiers in cell and developmental biology · 2023Review
- Article
- Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade.British journal of cancer · 2022Article
- Exploring prognostic indicators in the pathological images of ovarian cancer based on a deep survival network.Frontiers in genetics · 2022Article
- The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer.Frontiers in immunology · 2022Review
- Signatures associated with homologous recombination deficiency and immune regulation to improve clinical outcomes in patients with lung adenocarcinoma.Frontiers in oncology · 2022Article
- Development and validation of a novel fibroblast scoring model for lung adenocarcinoma.Frontiers in oncology · 2022Article
- Development and validation of a robust necroptosis related classifier for colon adenocarcinoma.Frontiers in genetics · 2022Article
- TRPs in Ovarian Serous Cystadenocarcinoma: The Expression Patterns, Prognostic Roles, and Potential Therapeutic Targets.Frontiers in molecular biosciences · 2022Article
- Development and validation of a combined glycolysis and immune prognostic signature for lung squamous cell carcinoma.Frontiers in genetics · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer patients with homologous recombination deficiency (HRD) tumors would benefit from PARP inhibitor (PARPi) therapy. However, patients with HRD tumors account for less than 50% of the whole cohort, so new biomarkers still need to be developed. Based on the data from the SNP array and somatic mutation profiles in the ovarian cancer genome, we found that high frequency of actionable mutations existed in patients with non-HRD tumors. Through transcriptome analysis, we identified that a downstream target of the cGAS-STING pathway, CXCL11, was upregulated in HRD tumors and could be used as a predictor of survival outcome. Further comprehensive analysis of the tumor immune microenvironment (TIME) revealed that CXCL11 expression signature was closely correlated with cytotoxic cells, neoantigen load and immune checkpoint blockade (ICB). Clinical trial data confirmed that the expression of CXCL11 could be used as a biomarker for anti-PD-1/PD-L1 therapy. Finally, in vivo and in vitro experiments showed that cancer cells with PARPi treatment increased the expression of CXCL11. Collectively, our study not only provides biomarkers of ovarian cancer complementary to the HRD score but also introduces a potential new perspective for identifying prognostic biomarkers of immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.